Triptans and troponin: a case report by Weder, C R & Schneemann, M
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Triptans and troponin: a case report
Weder, C R; Schneemann, M
Weder, C R; Schneemann, M (2009). Triptans and troponin: a case report. Orphanet Journal of Rare Diseases, 4:15.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Orphanet Journal of Rare Diseases 2009, 4:15.
Weder, C R; Schneemann, M (2009). Triptans and troponin: a case report. Orphanet Journal of Rare Diseases, 4:15.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Orphanet Journal of Rare Diseases 2009, 4:15.
Triptans and troponin: a case report
Abstract
This case report describes for the first time acute coronary syndrome in a 67-year old patient after oral
intake of naratriptan for migraine. So far in the literature, only sumatriptan, zolmitriptan and frovatriptan
have been described to cause acute coronary syndromes. A 67-year old Swiss woman with thoracic pain
after intake of 2.5 mg naratriptan presented with T-wave inversions in the ECG and a positive
troponin-T at our hospital. Coronary angiography showed normal coronary arteries. Naratriptan-induced
coronary vasospasms were thought to have caused the acute coronary syndrome.Triptans should not be
prescribed in patients with pre-existing coronary heart disease. However, triptans can also cause acute
coronary syndromes in patients without coronary heart disease--as described in our case report. Severe
or persistent thoracic pain after intake of triptans should therefore be investigated accordingly.
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Abstract
This case report describes for the first time acute coronary syndrome in a 67-year old patient after
oral intake of naratriptan for migraine. So far in the literature, only sumatriptan, zolmitriptan and
frovatriptan have been described to cause acute coronary syndromes.
A 67-year old Swiss woman with thoracic pain after intake of 2.5 mg naratriptan presented with T-
wave inversions in the ECG and a positive troponin-T at our hospital. Coronary angiography
showed normal coronary arteries. Naratriptan-induced coronary vasospasms were thought to
have caused the acute coronary syndrome.
Triptans should not be prescribed in patients with pre-existing coronary heart disease. However,
triptans can also cause acute coronary syndromes in patients without coronary heart disease – as
described in our case report. Severe or persistent thoracic pain after intake of triptans should
therefore be investigated accordingly.
Background
Triptans are an established treatment of acute migraine
attacks[1]. By activating 5HT1B/1D-receptors they lead to
vasoconstriction of cerebral blood vessels which are
dilated during migraine attacks[2]. Moreover, they reduce
secretion of vasoactive peptides and conduction of pain
stimuli over the cerebral cortex[2]. Although triptans exert
their therapeutic effect through cerebral vasoconstriction,
studies have also documented vasoconstriction in the cor-
onary, pulmonary, and systemic vasculature[3]. Under
treatment with triptans in 1–7% thoracic pain occurs,
which is mostly transient, mild and without lasting
ischemia[4]. The incidence of myocardial infarction
under triptans is estimated to be very low[4]. Most pub-
lished case reports refer to myocardial infarction after the
use of sumatriptan (subcutaneous [5-8,14] oral [9-12]
and nasal[13] application), whereas both stenotic [6-
8,12] and normal [9-11,13,14] coronary arteries could be
found angiographically. Besides sumatriptan, acute coro-
nary syndrome has been described after the use of zol-
mitriptan [15,16] and frovatriptan[17].
Here we report for the first time acute coronary syndrome
in a 67-year old Swiss patient after oral intake of nar-
atriptan for migraine. Migraine attacks stopped com-
pletely in our patient after implementation of the calcium
blocker amlodipine as antihypertensive treatment. Differ-
ent calcium blockers can be used for migraine prophylaxis
(verapamil, diltiazem, nifedipine)[18], but are not recom-
mended as first choice treatment. The efficacy of
amlodipine as preventive migraine treatment has been
reported in only 2 case reports so far [18,19].
Case presentation
A 67-year old patient was submitted to our emergency
unit because of thoracic pain. Her medical history was
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migraine was controlled satisfactorily with naratriptan,
which the patient has been taking for the last five years on
an as-needed basis. So far, the patient has never experi-
enced any adverse event after taking naratriptan. The
patient had a positive history for arterial hypertension and
colon irritabile and had a regular medication of lisinopril
5 mg once daily, paracetamol 1 g once daily, magnesium
5 mg two times daily and cholestyramin 4 g once daily.
On the evening before hospital admission the patient suf-
fered from an acute migraine attack with headaches and
nausea so that she took 2.5 mg naratriptan orally as usual.
Thereafter the headaches eased off. 30 to 60 minutes later
the patient felt thoracic pain. During the following night
the pain increased steadily with radiation to the neck. The
next morning the patient went to see her family doctor. As
the patient presented with T-wave inversions on the ECG
in the first four precordial leads and a positive test for tro-
ponin the family doctor sent the patient to our hospital
with the diagnosis of an acute coronary syndrome.
The ECG on admission showed T-wave inversions in leads
V1 through V4 (figure 1). Creatine Kinase (CK) rose to a
peak of 518 U/l (normal value < 167 U/l) and troponin-T
to 0.42 ug/l (normal value < 0.1 ug/l). The patient was ini-
tially treated with acetylsalicylic acid 500 mg, clopidogrel
600 mg, heparine 5000 IU, oxygen and nitrates. Coronary
angiography showed patent coronary arteries (figure 2)
and ventriculography of the left ventricle a normal ejec-
tion fraction of 59%. Naratriptan was stopped as as-
needed migraine medication and an antihypertensive
treatment with the calcium blocker amlodipine was
implemented. The patient was discharged in good condi-
tion after four days. Her cardiac status remained stable
two years after the acute coronary syndrome. Moreover,
the patient reported that she did no longer suffer from
migraine attacks since taking amlodipine.
Discussion
We postulated transient, prolonged coronary vasospasm
caused by the vasoconstrictor properties of naratripan as the
pathophysiological mechanism for the acute coronary syn-
drome in this patient without underlying coronary heart dis-
ease. The long duration of the patient's symptoms can be
explained by the long half life of naratriptan, which is six
hours. To prove our hypothesis of triptan-induced coronary
vasospasm, a provocative testing with naratriptan could have
been performed during the coronary angiography. However,
as the history was very suggestive we abstained from this pro-
cedure. Besides the intake of naratriptan no other triggers for
migraine were evident in this patient.
Electrocardiogram with T-wave inversions in leads V1 to V4Figu e 1
Electrocardiogram with T-wave inversions in leads V1 to V4.Page 2 of 3
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One important differential diagnosis in our patient is car-
diac headache which is an extremely rare atypical presen-
tation of coronary syndrome[20]. However, the
presentation of our patient was more likely explained by
triptan-induced coronary vasospasm as the patient was
known for migraine for many years, migraine attacks had
always a typical presentation, responded well to triptans
and were not exertional. Moreover, the patient's actual
chest pain occurred after taking naratriptan when the
migraine had already eased off.
The fact that migraine attacks stopped completely after
implementation of amlodipine as antihypertensive treat-
ment can be explained by the vasodilatatory effects of
amlodipine.
Conclusion
Triptans should not be prescribed in patients older than
65 years of age and in patients with underlying coronary
heart disease. But also patients without coronary heart dis-
ease may develop acute coronary syndromes after intake
of triptans, as described in this case report. Severe or per-
sistent thoracic pain after intake of triptans should be
investigated promptly.
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Coronarangiography with patent coronary arteriesFigure 2
Coronarangiography with patent coronary arteries.
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